News
Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...
Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...
Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...
Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
3hon MSN
Layoffs loom at weight loss drug Wegovy's maker Novo Nordisk as slowing sales threaten job cuts
Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...
The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results